223 related articles for article (PubMed ID: 24349500)
1. KIR, HLA, and IL28B variant predict response to antiviral therapy in genotype 1 chronic hepatitis C patients in Japan.
Nozawa Y; Umemura T; Joshita S; Katsuyama Y; Shibata S; Kimura T; Morita S; Komatsu M; Matsumoto A; Tanaka E; Ota M
PLoS One; 2013; 8(12):e83381. PubMed ID: 24349500
[TBL] [Abstract][Full Text] [Related]
2. KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.
Umemura T; Ota M; Katsuyama Y; Wada S; Mori H; Maruyama A; Shibata S; Nozawa Y; Kimura T; Morita S; Joshita S; Komatsu M; Matsumoto A; Kamijo A; Kobayashi M; Takamatsu M; Yoshizawa K; Kiyosawa K; Tanaka E
Hum Immunol; 2014 Aug; 75(8):822-6. PubMed ID: 24929144
[TBL] [Abstract][Full Text] [Related]
3. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study.
Suppiah V; Gaudieri S; Armstrong NJ; O'Connor KS; Berg T; Weltman M; Abate ML; Spengler U; Bassendine M; Dore GJ; Irving WL; Powell E; Hellard M; Riordan S; Matthews G; Sheridan D; Nattermann J; Smedile A; Müller T; Hammond E; Dunn D; Negro F; Bochud PY; Mallal S; Ahlenstiel G; Stewart GJ; George J; Booth DR;
PLoS Med; 2011 Sep; 8(9):e1001092. PubMed ID: 21931540
[TBL] [Abstract][Full Text] [Related]
4. Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection.
Vidal-Castiñeira JR; López-Vázquez A; Díaz-Peña R; Alonso-Arias R; Martínez-Borra J; Pérez R; Fernández-Suárez J; Melón S; Prieto J; Rodrigo L; López-Larrea C
J Virol; 2010 Jan; 84(1):475-81. PubMed ID: 19846535
[TBL] [Abstract][Full Text] [Related]
5. Lack of killer immunoglobulin-like receptor 2DS2 (KIR2DS2) and KIR2DL2 is associated with poor responses to therapy of recurrent hepatitis C virus in liver transplant recipients.
Askar M; Avery R; Corey R; Lopez R; Thomas D; Pidwell D; Eghtesad B; Miller C; Fung J; Zein NN
Liver Transpl; 2009 Nov; 15(11):1557-63. PubMed ID: 19877200
[TBL] [Abstract][Full Text] [Related]
6. Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b.
Tsubota A; Shimada N; Atsukawa M; Abe H; Kato K; Ika M; Matsudaira H; Nagatsuma K; Matsuura T; Aizawa Y
J Gastroenterol Hepatol; 2014 Jan; 29(1):144-50. PubMed ID: 24117654
[TBL] [Abstract][Full Text] [Related]
7. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.
Naggie S; Osinusi A; Katsounas A; Lempicki R; Herrmann E; Thompson AJ; Clark PJ; Patel K; Muir AJ; McHutchison JG; Schlaak JF; Trippler M; Shivakumar B; Masur H; Polis MA; Kottilil S
Hepatology; 2012 Aug; 56(2):444-54. PubMed ID: 22331604
[TBL] [Abstract][Full Text] [Related]
8. Association of killer cell immunoglobulin-like receptors with spontaneous clearance of hepatitis C virus in the Chinese population.
Shan Z; Huang J; Liao Q; Huang K; Wang M; Xu R; Tang X; Zhang W; Nelson K; Fu Y; Li C; Rong X
Transfusion; 2018 Apr; 58(4):1028-1035. PubMed ID: 29446443
[TBL] [Abstract][Full Text] [Related]
9. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.
Sakamoto N; Nakagawa M; Tanaka Y; Sekine-Osajima Y; Ueyama M; Kurosaki M; Nishida N; Tamori A; Yuki NS; Itsui Y; Azuma S; Kakinuma S; Hige S; Itoh Y; Tanaka E; Hiasa Y; Izumi N; Tokunaga K; Mizokami M; Watanabe M;
J Med Virol; 2011 May; 83(5):871-8. PubMed ID: 21360545
[TBL] [Abstract][Full Text] [Related]
10. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
[TBL] [Abstract][Full Text] [Related]
11. Response to treatment in Brazilian patients with chronic hepatitis C is associated with a single-nucleotide polymorphism near the interleukin-28B gene.
Grandi T; da Silva CM; Amaral KM; Picon PD; Costi C; da Fré NN; Fiegenbaum M; Niel C; Rossetti ML
Mem Inst Oswaldo Cruz; 2013 Feb; 108(1):48-53. PubMed ID: 23440114
[TBL] [Abstract][Full Text] [Related]
12. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
[TBL] [Abstract][Full Text] [Related]
13. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
[TBL] [Abstract][Full Text] [Related]
14. [Association of interleukin 28B polymorphisms with response to pegylatedinterferon plus ribavirin therapy for chronic hepatitis C].
Xu H; Guo LL; He LL; Chen Y; Liu K; Lei BJ; Lei XZ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Nov; 43(6):855-9. PubMed ID: 23387213
[TBL] [Abstract][Full Text] [Related]
15. Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.
Kim SR; El-Shamy A; Imoto S; Kim KI; Ide YH; Deng L; Shoji I; Tanaka Y; Hasegawa Y; Ota M; Hotta H
J Gastroenterol; 2012 Oct; 47(10):1143-51. PubMed ID: 22441534
[TBL] [Abstract][Full Text] [Related]
16. Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.
Boglione L; Cusato J; Allegra S; Cariti G; Di Perri G; D'Avolio A
Arch Virol; 2015 Aug; 160(8):2009-17. PubMed ID: 26060059
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.
Hu CC; Lin CL; Chang LC; Chien CH; Chen LW; Liu CJ; Chien RN
BMC Infect Dis; 2015 Mar; 15():156. PubMed ID: 25888020
[TBL] [Abstract][Full Text] [Related]
18. Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.
Tahata Y; Hiramatsu N; Oze T; Urabe A; Morishita N; Yamada R; Yakushijin T; Hosui A; Oshita M; Kaneko A; Hagiwara H; Mita E; Ito T; Yamada Y; Inada M; Katayama K; Tamura S; Imai Y; Hikita H; Sakamori R; Yoshida Y; Tatsumi T; Hayashi N; Takehara T
J Med Virol; 2016 Oct; 88(10):1776-84. PubMed ID: 26991414
[TBL] [Abstract][Full Text] [Related]
19. Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study.
Shimada N; Toyoda H; Tsubota A; Ide T; Takaguchi K; Kato K; Kondoh M; Matsuyama K; Kumada T; Sata M
J Gastroenterol; 2014 Nov; 49(11):1485-94. PubMed ID: 24287582
[TBL] [Abstract][Full Text] [Related]
20. Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.
Jia Z; Ding Y; Tian S; Niu J; Jiang J
PLoS One; 2012; 7(9):e45698. PubMed ID: 23029188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
